Xortx finalizes $2.7 million prospectus supplement and concurrent private placement for the offering of units

Not for distribution to united states news wire servicesor for dissemination in the united states calgary, alberta, march 04, 2024 (globe newswire) -- xortx therapeutics inc. (“xortx” or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a second tranche closing (the “second tranche closing”) of gross proceeds of cad $224,850 under previously announced offering, including cad $99,000 in a concurrent private placement of the company in connection with international subscribers. the company completed the second tranche closing under the same terms of the previously announced first tranche closing on february 15, 2024 (the “first tranche closing”).
XRTX Ratings Summary
XRTX Quant Ranking